Baudax Bio, Inc. announced that the FDA has approved the New Drug Application (NDA) for Anjeso (meloxicam injection), which is indicated for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.
The FDA has approved the Bio-Rad BioPlex 2200 HIV Ag-Ab assay, the first FDA-approved diagnostic that differentiates between HIV-1 antibodies,...
bluebird bio, Inc. has announced the filing by 2seventy bio of an updated Form 10 Registration Statement with the U.S. Securities and Exchange Commission (SEC).
Horizon Therapeutics plc and Viela Bio, Inc.announced the companies have entered into a definitive agreement under which Horizon will acquire all of the issued and outstanding shares of Viela Bio, Inc. common stock for $53.00 per share in cash, which represents a fully diluted equity value of approximately $3.05 billion, or approximately $2.67 billion net of Viela's cash and cash equivalents.
bluebird bio, Inc. announced its intent to separate its severe genetic disease and oncology businesses into differentiated and independent publicly traded companies.
The FDA) has approved Bio-T-Gel, which is licensed by BioSante to Teva Pharmaceuticals USA, Inc. Bio-T-Gel is a testosterone gel...
Sandoz, a Novartis division, announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT 1706).
Sophiris Bio Inc.developing PRX 302 (topsalysin) for the treatment of symptoms of Benign Prostatic Hyperplasia (BPH, enlarged prostate) and the...